Everybody deserves to be treated differently
The TailorDose® approach is based on a patented method, suitable for determination of the active dose of cytostatic drugs. The aim is to customize – “Tailor” – the chemotherapy for each individual patient. TailorDose is a Swedish patented technology that provides an easy method for determining the levels of covalently binding substances in cells or whole blood. The method is tailor made and can detect adducts with a sensitivity down to low pico molar concentrations.
Today, dosing of cytostatic drugs are based on the patient’s body surface area (mg/m2, BSA) and it is well known that this estimate leads to suboptimal dosing of a large proportion of the patients (drug dependent often over 50%). Our own data from a clinical study involving 150 patients receiving cyclophosphamide indicate that 22% of the subjects are given a dose that is too low (affecting the efficacy of the treatment) and 17% are given a dose which is too high (leading to higher risk of severe adverse side effects, often expressed late in the therapy). One single blood sample, taken at the routine control a few days after the very first dose, is sufficient to obtain an exact dose measure to “TailorDose®” the therapy.
The market for such a product is large, only in Sweden approximately 4500 patients are treated with cyclophosphamide each year. The product is currently being CE-marked and key opinion leaders such as prof. Jonas Bergh are directly involved in research to validate clinical benefits.
An interesting opportunity for pharmaceutical companies developing new cancer therapies would be to use TailorDose® as a tool to access more clinical information in clinical trials, also closed trials, and as companion diagnostics for products already on market. These three opportunities should be of high interest as the intra-individual variation of AUC-dose can be as high as 15-fold for e.g. Imbruvica®.